This published study protocol for the MedSeq trials includes a description of the study design; recruitment, enrollment, and sample size plan; patient exclusion/inclusion criteria; and process of interpreting WGS results and delivering them to physicians. It also includes an example of a general genome report as well as a cardiac risk report.

This document is the study protocol of the Institutional and Professional Impact of Genomic Sequencing in Cancer Care study. Appendices include the following: Email Notification to Oncologists about Study Implementation Information Sessions, Email Invitation to Oncologists to Participate in Cognitive Testing, Email Invitation to Attend an Initial Clinical Genomics Evaluation Committee Meeting, Physician Baseline Survey, Email Notification to Oncologists to Complete the Baseline Survey, Follow up Email Notification to Oncologists to Complete the Baseline Survey, New Physician Post-disclosure Survey – Informative Results, Old Physician Post-disclosure Survey, Physician Post-Disclosure Survey – Uninformative Results, Email Notification to Oncologists to Complete the Post-disclosure Survey, Reminder Email Notification to Oncologists to Complete the Post-disclosure Survey, Email Invitation for the Baseline Qualitative Interview, and Email Invitation for the One-Year Follow up Qualitative Interview.

This document is the Use of Sequencing to Guide the Care of Cancer Patients study protocol. Appendices include the following: Measures for Patient Baseline, Email Notification to Patients to Complete Baseline Survey, Measures for Patient Post-Disclosure Survey in the Setting of Uninformative Sequencing Results, Measures for Patient Post-Disclosure Survey in the Setting of Informative Sequencing Results, Training plan for CRCs, Patient Baseline Reminder Letter, Patient Post-Disclosure Email Invitation and reminder email, Patient Post-Disclosure Reminder invitation and reminder letter, CanSeq Patient Informed Consent Interview Guide, Patient Information brochure, Post-Disclosure email introduction, ACMG Guidelines, Patient Preferences Communication, Gift Card Thank You Letter, and Patient Post-Disclosure Interview.

The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.

The Personalized Medicine Based on Molecular Profiling of Patients with Cancer implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.

The Manual for Deliberative Focus Group Discussions (dFGDs) on Feedback of Individual Findings in Genomic Research was originally developed for use among adults and adolescents enrolled in genomics research in South Africa and Botswana. However, the manual may be adapted for use in other settings and in studies using dFGDs on topics other than feedback of individual genetic results. The first section provides education on genes and how they impact on health. An animated video to describe these concepts was developed. The second section has embedded case study scenarios and an interview schedule which are used to guide deliberations.

The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.